Long-Term Survival Outcomes with First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients with Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis.
JOURNAL OF THORACIC ONCOLOGY（2025）
Key words
Non-small cell lung cancer,PD-L1,Immuno- therapy,Nivolumab,Ipilimumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined